Cannabinoid receptors as therapeutic targets

Current Pharmaceutical Design

Volumn 12, Issue 14, 2006, Pages 1751-1769

  Pavlopoulos, Spiro ^a   Thakur, Ganesh A ^b   Nikas, Spyros P ^b   Makriyannis, Alexandros ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Agonist; Aminoalkylindoles; Antagonist; Cannabinoid; Diarylpyrazoles; Endocannabinoids; Pharmacophore; Receptors; Selectivity

Indexed keywords

11 HYDROXYDRONABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; ADAMANTANE DERIVATIVE; ADAMANTYL DELTA8 TETRAHYDROCANNABINOL; AM 1708; AM 4030A; AM 4030B; AM 411; AMG 3; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CARRIER PROTEIN; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; ENZYME; G PROTEIN COUPLED RECEPTOR; LIGAND; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NOLADIN ETHER; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DESIGN; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME SUBSTRATE; HISTORY; HUMAN; NEUROMODULATION; NONHUMAN; PLANT; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, CANNABINOID;

EID: 33646508785     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873743     Document Type: Review

References (228)

1. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000; 108(1-2): 1-13.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Stucture of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365(6441): 61-5.
4. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289(5480): 739-45.
5. Filppula S, Yaddanapudi S, Mercier R, Xu W, Pavlopoulos S, Makriyannis A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. J Pept Res 2004; 64(6): 225-36.
6. Song ZH, Slowey CA, Hurst DP, Reggio PH. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol 1999; 56(4): 834-40.
7. Haslam CP, Brown AJ, Daniels D, Wall ID. In Symposium on the Cannabinoids; International Cannabinoid Research Society: Burlington, Vermont, USA, 2004; 123
8. Gouldson P, Calandra B, Legoux P, Kerneis A, Rinaldi-Carmona M, Barth F, et al. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 401(1): 17-25.
9. Reggio PH. Pharmacophores for ligand recognition and activation/ inactivation of the cannabinoid receptors. Curr Pharm Des 2003; 9(20): 1607-33.
10. von Heijne G. Proline kinks in transmembrane alpha-helices. J Mol Biol 1991; 218(3): 499-503.
11. Chakrabarti P, Chakrabarti S. C-H. O hydrogen bond involving proline residues in alpha-helices. J Mol Biol 1998; 284(4): 867-73.
12. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001; 276(31): 29171-7.
13. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21(1): 90-113.
14. Deupi X, Olivella M, Govaerts C, Ballesteros JA, Campillo M, Pardo L. Ser and Thr residues modulate the conformation of prokinked transmembrane alpha-helices. Biophys J 2004; 86(1 Pt 1): 105-15.
15. Barnett Norris J, Hurst DP, Buehner K, Ballesteros J, Guarnieri F, Reggio PH. Agonist Alkyl Tail Interaction with Cannabinoid CB1 Receptor V6.43/I6.46 Groove Induces a Helix 6 Active Conformation. Int J Quantum Chem 2002; 88: 76-86.
16. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001; 276(12): 9279-90.
17. Hulme EC, Lu ZL, Ward SD, Allman K, Curtis CA. The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 1999; 375(1-3): 247-60.
18. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 1996; 35(34): 11149-59.
19. Xie XQ, Chen JZ, Billings EM. 3D structural model of the Gprotein-coupled cannabinoid CB2 receptor. Proteins 2003; 53(2): 307-19.
20. Rhee MH, Nevo I, Levy R, Vogel Z. Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor. FEBS Lett 2000; 466(2-3): 300-4.
21. Feng W, Song ZH. Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochem Pharmacol 2003; 65(7): 1077-85.
22. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002; 277(43): 40989-96.
23. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 2004; 279(46): 48024-37.
24. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16(3): 89-97.
25. Tao Q, McAllister SD, Andreassi J, Nowell KW, Cabral GA, Hurst DP, et al. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol 1999; 55(3): 605-13.
26. Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 1996; 49(5): 891-6.
27. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, et al. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 2003; 46(24): 5139-52.
28. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3(10): 745-55.
29. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95(2): 127-35.
30. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95(2): 185-90.
31. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002; 95(2): 103-17.
32. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002; 95(2): 191-202.
33. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95(2): 175-84.
34. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95(2): 203-20.
35. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95(2): 165-74.
36. Hansen HS, Moesgaard B, Petersen G, Hansen HH. Putative neuroprotective actions of N-acyl-ethanolamines. Pharmacol Ther 2002; 95(2): 119-26.
37. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605-13.
38. Howlett AC, Song C, Berglund BA, Wilken GH, Pigg JJ. Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol Pharmacol 1998; 53(3): 504-10.
39. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279(Pt 1): 129-34.
40. Di-Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75(6): 2434-44.
41. Kunos G, Batkai S, Offertaler L, Mo F, Liu J, Karcher J, et al. The quest for a vascular endothelial cannabinoid receptor. Chem Phys Lipids 2002; 121(1-2): 45-56.
42. Mo FM, Offertaler L, Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 2004; 489(1-2): 21-7.
43. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96(10): 5780-5.
44. Breivogel CS, Griffin G, Di-Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1): 155-63.
45. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 2003; 10(2): 116-28.
46. Rouach N, Nicoll RA. Endocannabinoids contribute to short-term but not long-term mGluR-induced depression in the hippocampus. Eur J Neurosci 2003; 18(4): 1017-20.
47. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106(1): 1-4.
48. Hajos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002; 43(4): 503-10.
49. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96(24): 14136-41.
50. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33(1 Pt 2): 429-34.
51. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999; 65(6-7): 573-95.
52. Mechoulam R, Ben Shabat S, Hanus L, Fride E, Vogel Z, Bayewitch M, et al. Endogenous cannabinoid ligands-chemical and biological studies. J Lipid Mediat Cell Signal 1996; 14(1-3): 45-9.
53. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
54. Mechoulam R, Fride E, Di-Marzo V. Endocannabinoids. Eur J Pharmacol 1998; 359(1): 1-18.
55. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98(7): 3662-5.
56. Suhara Y, Takayama H, Nakane S, Miyashita T, Waku K, Sugiura T. Synthesis and biological activities of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues. Chem Pharm Bull 2000; 48(7): 903-7.
57. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 1999; 274(5): 2794-801.
58. Di-Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372(6507): 686-91.
59. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 1996; 16(12): 3934-42.
60. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004; 279(7): 5298-305.
61. Piomelli D, Giuffrida A, Calignano A, Rodriguez-de-Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21(6): 218-24.
62. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4(11): 873-84.
63. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094-7.
64. Giuffrida A, Parsons LH, Kerr TM, Rodriguez-de-Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2(4): 358-63.
65. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 2003; 100(7): 4269-74.
66. Natarajan V, Schmid PC, Reddy PV, Schmid HH. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem 1984; 42(6): 1613-9.
67. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 2004; 101(23): 8756-61.
68. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 1997; 69(2): 631-8.
69. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995; 270(11): 6030-5.
70. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993; 46(5): 791-6.
71. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384(6604): 83-7.
72. Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 1997; 94(6): 2238-42.
73. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, et al. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 1999; 42(5): 896-902.
74. Patricelli MP, Cravatt BF. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry 1999; 38(43): 14125-30.
75. Patricelli MP, Cravatt BF. Clarifying the catalytic roles of conserved residues in the amidase signature family. J Biol Chem 2000; 275(25): 19177-84.
76. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 1998; 331(Pt 1): 15-9.
77. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998; 422(1): 69-73.
78. Arreaza G, Devane WA, Omeir RL, Sajnani G, Kunz J, Cravatt BF, et al. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci Lett 1997; 234(1): 59-62.
79. Kurahashi Y, Ueda N, Suzuki H, Suzuki M, Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem Biophys Res Commun 1997; 237(3): 512-5.
80. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000; 97(10): 5044-9.
81. Patricelli MP, Cravatt BF. Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase. Biochemistry 2001; 40: 6107-15.
82. Boger DL, Sato H, Lerner AE, Austin BJ, Patterson JE, Patricelli MP, et al. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg Med Chem Lett 1999; 9(2): 265-70.
83. Boger DL, Fecik RA, Patterson JE, Miyauchi H, Patricelli MP, Cravatt BF. Fatty acid amide hydrolase substrate specificity. Bioorg Med Chem Lett 2000; 10(23): 2613-6.
84. Schmid P, Zuzarte-Augustin M, Schmid H. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 1985; 260(26): 14145-9.
85. Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994; 269(37): 22937-40.
86. De-Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, et al. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 1997; 231(1): 82-8.
87. Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 1997; 231(1): 217-21.
88. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci USA 1999; 96(10): 5786-90.
89. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48(3): 443-50.
90. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998; 38: 179-200.
91. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998; 284(1): 291-7.
92. Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 1997; 9(2): 199-203.
93. Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 1997; 120(8): 1397-8.
94. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 1998; 71(4): 1525-34.
95. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276(6 Pt 2): H2085-93.
96. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992; 106(2): 231-2.
97. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992; 89(9): 3825-9.
98. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995; 15(10): 6552-61.
99. Pan X, Ikeda SR, Lewis DL. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 1996; 49(4): 707-14.
100. Henry DJ, Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 1995; 186(2-3): 91-4.
101. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78(1): 43-50.
102. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 1996; 273(5282): 1719-22.
103. Derkinderen P, Enslen H, Girault JA. The ERK/MAP-kinases cascade in the nervous system. Neuroreport 1999; 10(5): R24-34.
104. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312(Pt 2): 637-41.
105. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272(35): 22330-9.
106. Rueda D, Galve-Roperh I, Haro A, Guzman M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 2000; 58(4): 814-20.
107. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6(3): 313-9.
108. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996; 237(3): 704-11.
109. Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le-Fur G, Casellas P. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 1995; 270(23): 13973-80.
110. Dewey WL, Martin BR, In: Smith CH Ed, CRC Handbook Stereoisomers: Drugs Psychopharmacology. Boca Raton, CRC Press. 1984; 317-26
111. Martin BR, Balster RL, Razdan RK, Harris LS, Dewey WL. Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci 1981; 29(6): 565-74.
112. Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J Med Chem 1975; 18(7): 700-3.
113. Wilson RS, May EL, Dewey WL. Some 9-hydroxycannabinoidlike compounds. Synthesis and evaluation of analgesic and behavioral properties. J Med Chem 1979; 22(7): 886-8.
114. Wilson RS, May EL, Martin BR, Dewey WL. 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. J Med Chem 1976; 19(9): 1165-7.
115. Makriyannis A, Rapaka RS. The molecular basis of cannabinoid activity. Life Sci 1990; 47(24): 2173-84.
116. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986; 38(2): 75-149.
117. Khanolkar AD, Palmer SL, Makriyannis A. Molecular probes for the cannabinoid receptors. Chem Phys Lipids 2000; 108(1-2): 37-52.
118. Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem Phys Lipids 2002; 121(1-2): 3-19.
119. Thakur GA, Nikas SP, Li C, Makriyannis A. In: Pertwee CH Ed, Cannabinoids, Handbook of Experimental Pharmacology. New York, Springer-Verlag. 2005; 210-46.
120. Thakur GA, Nikas SP, Makriyannis A. CB1 cannabinoid receptor ligands. Mini Rev Med Chem 2005; 5(7): 631-40.
121. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2): 161-202.
122. Johnson MR, Melvin LS. In: Mechoulam CH Ed, Cannabinoids as therapeutic agents, Boca Raton, CRC Press.1986; 121-45.
123. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 1988; 247(3): 1046-51.
124. Mechoulam R, Devane WA, Glaser R. In: Nahas CH Ed, Marijuana and Medicine, Totowa, Humana Press. 1999; 65-90
125. Makriyannis A, Goutopoulos A. In: Makriyannis CH Ed, Drug Discovery Strategies and Methods. New York, Marcel Dekker, Inc. 2004; 89-128.
126. Adams R, Harfenist M, Loewe S. New analogs of tetrahydrocannabinol. XIX. J Am Chem Soc 1949; 71: 1624-8.
127. 8-THC, a very potent CB1 agonist. Tetrahedron 2001; 57(36): 7607-12.
128. Huffman JW, Miller JR, Liddle J, Yu S, Thomas BF, Wiley JL, et al. Structure-activity relationships for 1′,1′-dimethylalkyl-Delta8-tetrahydrocannabinols. Bioorg Med Chem 2003; 11(7): 1397-410.
129. 8-tetrahydro-cannabinol analogs. J Heterocycl Chem 1996; 33(3): 559-62.
130. Krishnamurthy M, Ferreira AM, Moore BM. Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. Bioorg Med Chem Lett 2003; 13(20): 3487-90.
131. Nadipuram AK, Krishnamurthy M, Ferreira AM, Li W, Moore BM. Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. Bioorg Med Chem 2003; 11(14): 3121-32.
132. Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1′-substituted delta 8-tetrahydrocannabinols. J Med Chem 1998; 41(7): 1195-200.
133. Papahatjis DP, Nikas S, Tsotinis A, Vlachou M, Makriyannis A. A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules. Chem Lett 2001; 3: 192-3.
134. Papahatjis DP, Nikas SP, Andreou T, Makriyannis A. Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols. Bioorg Med Chem Lett 2002; 12(24): 3583-6.
135. Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, et al. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem 2003; 46(15): 3221-9.
136. Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem 2005; 48(14): 4576-85.
137. Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA, et al. Unsaturated side chain β-11-hydroxyhexahydrocannabinol analogs. J Med Chem 1996; 39(19): 3790-6.
138. Martin BR, Jefferson RG, Winckler R, Wiley JL, Thomas BF, Crocker PJ, et al. Assessment of structural commonality between tetrahydrocannabinol and anandamide. Eur J Pharmacol 2002; 435(1): 35-42.
139. 8-tetrahydrocannabinol series. Tetrahedron 1999; 55(49): 13907-26.
140. 8-THC analogs. Pharmacol Biochem Behav 1991; 40(3): 509-12.
141. 9-THC. Pharmacol Biochem Behav 1993; 46(2): 295-301.
142. Tius MA, Busch-Petersen J, Marris AR. Synthesis of a bifunctional cannabinoid ligand. J Chem Soc Chem Commun 1997; 19: 1867-8.
143. Tius MA, Kannangara GSK, Kerr MA, Grace KJS. Halogenated cannabinoid synthesis. Tetrahedron 1993; 49(16): 3291-304.
144. Nikas SP, Grzybowska J, Papahatjis DP, Charalambous A, Banijamali AR, Chari R, et al. The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. AAPS J 2004; 6(4): e30.
145. Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK. Novel cannabinol probes for CB1 and CB2 cannabinoid receptors. J Med Chem 2000; 43(20): 3778-85.
146. Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, et al. Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors. Bioorg Med Chem Lett 1996; 6(2): 189-94.
147. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 1996; 39(20): 3875-7.
148. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, et al. 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999; 7(12): 2905-14.
149. Huffman JW, Bushell SM, Miller JR, Wiley JL, Martin BR. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Δ8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg Med Chem 2002; 10(12): 4119-29.
150. Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M, Feigenbaum JJ, et al. Stereochemical requirements for cannabimimetic activity. NIDA Res Monogr 1987; 79: 15-30.
151. Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988; 44(9): 762-4.
152. Shohami E, Mechoulam R. Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. Drug Develop Res 2000; 50(3-4): 211-5.
153. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30(3): 548-54.
154. Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002; 1(10): 753-68.
155. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997; 40(20): 3228-33.
156. Yan G, Yin D, Khanolkar AD, Compton DR, Martin BR, Makriyannis A. Synthesis and pharmacological properties of 11-hydroxy-3-(1′,1′-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist. J Med Chem 1994; 37(16): 2619-22.
157. Devane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem 1992; 35(11): 2065-9.
158. Archer RA, Stark P, Lemberger L. In: Mechoulam CH Ed, Cannabinoids as therapeutic targets. Boca Raton, CRC Press. 1986; 85-103
159. Martin BR, Dewey WL, Harris LS, Beckner J. Marihuana-like activity of new synthetic tetrahydrocannabinols. Pharmacol Biochem Behav 1975; 3(5): 849-53.
160. 11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. Mol Pharmacol 1989; 35(4): 495-503.
161. Reggio PH, Greer KV, Cox SM. The importance of the orientation of the C9 substituent to cannabinoid activity. J Med Chem 1989; 32: 1630-5.
162. Chu C, Ramamurthy A, Makriyannis A, Tius MA. Synthesis of covalent probes for the radiolabeling of the cannabinoid receptor. J Org Chem 2003; 68(1): 55-61.
163. Drake DJ, Jensen RS, Busch-Petersen J, Kawakami JK, Concepcion-Fernandez-Garcia M, Fan P, et al. Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6β methyl, ethyl, and propyl analogues. J Med Chem 1998; 41(19): 3596-608.
164. Harrington PE, Stergiades IA, Erickson J, Makriyannis A, Tius MA. Synthesis of functionalized cannabinoids. J Org Chem 2000; 65(20): 6576-82.
165. Tius MA, Makriyannis A, Long Zou X, Abadji V. Conformationally restricted hybrids of CP-55,940 and HHC: stereoselective synthesis and activity. Tetrahedron 1994; 50: 2671-80.
166. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96(25): 14228-33.
167. Tius MA, Hill WA, Zou XL, Busch-Petersen J, Kawakami JK, Fernandez Garcia MC, et al. Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain. Life Sci 1995; 56(23-24): 2007-12.
168. Thakur GA, Palmer SL, Harrington PE, Stergiades IA, Tius MA, Makriyannis A. Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. J Biochem Biophys Methods 2002; 54(1-3): 415-22.
169. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann JL Jr, Wetzel JR, et al. Antinociceptive (aminoalkyl)indoles. J Med Chem 1991; 34(3): 1099-110.
170. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992; 35(1): 124-35.
171. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, et al. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995; 38(16): 3094-105.
172. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
173. Xie XQ, Eissenstat M, Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci 1995; 56(23-24): 1963-70.
174. Hynes J Jr, Leftheris K, Wu H, Pandit C, Chen P, Norris DJ, et al. C-3 Amido-indole cannabinoid receptor modulators. Bioorg Med Chem Lett 2002; 12(17): 2399-402.
175. Wrobleski ST, Chen P, Hynes JJ, Lin S, Norris DJ, Pandit CR, et al.
176. D'Ambra TE, Eissenstat MA, Abt J, Ackerman JH, Bacon ER, Bell MR, et al. C-attached aminoalkylindoles: potent cannabinoid mimetics. Bioorg Med Chem Lett 1996; 6(1): 17-22.
177. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100(18): 10529-33.
178. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93(3): 239-45.
179. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid antagonist. Life Sci 1995; 56: 1949-55.
180. Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makriyannis A, Consroe P, et al. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci 1997; 61(9): PL115-8.
181. Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, et al. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol 1997; 321(1): R1-3.
182. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 1999; 126(3): 665-72.
183. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350(2-3): 240-4.
184. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999; 42(4): 769-76.
185. Nakamura-Palacios EM, Moerschbaecher JM, Barker LA. The pharmacology of SR 141716A: A review. CNS Drug Rev 1999; 5(1): 43-58.
186. Barth F, Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr Med Chem 1999; 6(8): 745-55.
187. Howlett AC, Wilken GH, Pigg JJ, Houston DB, Lan R, Liu Q, et al. Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction. J Neurochem 2000; 74(5): 2174-81.
188. Krishnamurthy M, Li W, Moore BM. Synthesis, biological evaluation, and structural studies on N1 and C5 substituted cycloalkyl analogues of the pyrazole class of CB1 and CB2 ligands. Bioorg Med Chem 2004; 12(2): 393-404.
189. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284(2): 644-50.
190. Francisco ME, Seltzman HH, Gilliam AF, Mitchell RA, Rider SL, Pertwee RG, et al. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). J Med Chem 2002; 45(13): 2708-19.
191. Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, Martin BR. Novel pyrazole cannabinoids: insights into CB1 receptor recognition and activation. J Pharmacol Exp Ther 2001; 296(3): 1013-22.
192. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 1997; 61(14): L 191-7.
193. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 1998; 70(1): 417-23.
194. Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R, Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997; 238(1-2): 84-6.
195. Lange JHM, Coolen HKAC, Van Stuivenberg HH, Dijksman JAR, Herremans AHJ, Ronken E, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem 2004; 47(3): 627-43.
196. Stoit AR, Lange JHM, den Hartog AP, Ronken E, Tipker K, van Stuivenberg HH, et al. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull 2002; 50(8): 1109-13.
197. Mussinu JM, Ruiu S, Mule AC, Pau A, Carai MA, Loriga G, et al. Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors. Bioorg Med Chem 2003; 11(2): 251-63.
198. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med Chem 1996; 39(2): 471-9.
199. Khanolkar AD, Makriyannis A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci 1999; 65(6-7): 607-16.
200. Palmer SL, Khanolkar AD, Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr Pharm Des 2000; 6(13): 1381-97.
201. Razdan RK, Mahadevan A. Recent advances in the synthesis of endocannabinoid related ligands. Chem Phys Lipids 2002; 121(1-2): 21-33.
202. Reggio PH. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2-3): 143-60.
203. Pinto JC, Potie F, Rice KC, Boring D, Johnson MR, Evans DM, et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994; 46(3): 516-22.
204. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997; 40(5): 659-67.
205. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 1998; 41(27): 5353-61.
206. Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, Martin BR. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci 1995; 56(23-24): 2041-8.
207. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995; 273(3): 1172-81.
208. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37(12): 1889-93.
209. Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem 2001; 9(7): 1673-84.
210. Barnett-Norris J, Hurst DP, Lynch DL, Guarnieri F, Makriyannis A, Reggio PH. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J Med Chem 2002; 45(17): 3649-59.
211. Rabinovich AL, Ripatti PO. On the conformational, physical properties and functions of polyunsaturated acyl chains. Biochim Biophys Acta 1991; 1085(1): 53-62.
212. Barnett-Norris J, Guarnieri F, Hurst DP, Reggio PH. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J Med Chem 1998; 41(24): 4861-72.
213. Rich MR. Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations. Biochim Biophys Acta 1993; 1178(1): 87-96.
214. Corey EJ, Cashman JR, Kantner SS, Wright SW. Rationally designed, potent competitive inhibitors of leukotriene biosynthesis. J Am Chem Soc 1984; 106(5): 1503-4.
215. Corey EJ, Iguchi S, Albright J, De B. Studies on the conformational mobility of arachidonic acid. Facile macrolactonization of 20-hydroxyarachidonic acid. Tetrahedron Lett 1983; 24(1): 37-40.
216. Tong W, Collantes ER, Welsh WJ, Berglund BA, Howlett AC. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med Chem 1998; 41(22): 4207-15.
217. Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, McCallion DS, Pertwee RG, et al. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J Med Chem 1997; 40(22): 3626-34.
218. Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chem 1997; 40(22): 3617-25.
219. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, et al. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands. 2001; 281(2): 444-51.
220. Mauler F, Mittendorf J, Horvath E, De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy) phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002; 302(1): 359-68.
221. Mauler F, Horvath E, de Vry J, Jaeger R, Schwarz T, Sandmann S, et al. BAY 38-7271: A novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 2003; 9(4): 343-58.
222. Mignani S, Hittinger A, Achard D, Bouchard H, Bouquerel J, Capet M, et al. Preparation of 1-bis(aryl)methyl-3-(alkylsulfonyl) arylmethyleneazetidines as cannabinoid CB1 receptor antagonists. PCT Int Appl 2000; pp. 239.
223. Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Navarro M, Serrano A, et al. Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem 2004; 47(11): 2939-42.
224. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 2001; 296(2): 420-5.
225. Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, et al. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg Med Chem 2004; 12(8): 1921-33.
226. Biegon A. Cannabinoids as neuroprotective agents in traumatic brain injury. Curr Pharm Des 2004; 10(18): 2177-83.
227. Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 2004; 10(6): 659-67.
228. Vandevoorde S, Lambert DM. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 2005; 11(20): 2647-68.